Understanding metastasis is integral to curative cancer treatments. Using a mouse genetic screening model, we identified Merm1/Wbscr22 as a novel metastasis promoter that includes a methyltransferase fold in its structure. Merm1 showed high levels of expression in invasive breast cancer. Ectopic expression of Merm1 in non-metastatic cells enhanced metastasis formation without affecting cell growth and motility. The intact methyltransferase fold of Merm1 was required for metastasis formation. Interestingly, Merm1 expression promoted cell survival after entrapment in the lung microvasculature.
Introduction
Metastasis and relapse are the leading causes of cancer mortality, resulting in more than five million deaths annually worldwide. Primary cancer is becoming increasingly treatable with the development of new cancer treatments, whereas metastasis remains difficult to control and treat. The difficulty in treating metastasis arises from the fact that metastasis is a dynamic and multistep pathology, and each step requires the cooperative action of a wide variety of genes (1, 2) . The complicated steps can result in the selection of untreatable metastatic tumor cells. Particularly in the vasculature, almost all cancer cells are destroyed because of strong selection pressures such as mechanical stress and immunologic assault, and less than 0.01% of tumor cells survive (3) . Mimicking the dynamic state in the vasculature would be an excellent tool to screen factors that are essential for the development of untreatable metastatic cancer cells.
In this study, we screened metastasis-promoting genes through an experimental metastasis model by intravenous injection. This metastasis model provides a good simulation of the cell dynamics of tumor metastasis in the vasculature. In fact, Minn et al. 
In vivo genetic screening
The cDNA library-infected CHO cells (CHO/library; 1x10 6 cells) were intravenously inoculated into the lateral tail vein of a 7-week-old female C57BL/6N mouse. After 28 days, the mouse lung was enzymatically digested. The digested lung was cultivated in medium containing geneticin (Invitrogen). Surviving CHO cells (CHO-M1) were intravenously inoculated, and CHO-M2 cells were separated using the same in vivo screening.
Western blotting
Cells were solubilized in a lysis buffer containing 2% NP-40, 0.2% sodium dodecyl sulfate and 0.5% sodium deoxycholate. We used antibodies to human Merm1 (GeneTex), mouse Merm1 (rabbit polyclonal antibody raised against amino acids 1-16), human Zac1 (Aviva), V5 tag (Invitrogen), p53AIP1 or β-actin (Sigma). The LAS3000 system (FUJIFILM) was used for visualization and quantification of signals. In some experiments, cells were incubated with 10 or 30 μM Nutlin-3 (Sigma) for 48 hours and then solubilized.
Immunostaining and immunohistochemistry
Cells were fixed and permeabilized with 4% paraformaldehyde and 0.2% Triton X in Labeling was carried out by incubation with a human Merm1 antibody (GeneTex) hours, and the lungs were extirpated. Cryosections of the lungs were visualized with the IX71 fluorescent microscope (Olympus), and the tumor foci in the field of view were counted using a modified hot-spot method (25) . Briefly, the area with the highest density of tumor foci was identified at low-power. The density of tumor foci in this area was then measured at high magnification.
Transcriptome analysis
A microarray analysis was performed according to standard Affymetrix protocols using GSE22065. To select significant genes based on differential expression, probes were selected with a fold change cutoff of >2-fold increase or decrease.
Statistical analysis
Data were shown as means ± SD. Mann-Whitney U test was performed to determine statistical significance in metastasis assays. Other assays were evaluated by Student's t test. P values less than 0.05 were considered statistically significant. All statistical tests were two-sided. 
Results

Identification of Merm1/Wbscr22 as a novel metastasis promoter.
To identify novel metastasis-promoting factors, we performed in vivo genetic screening using a mouse experimental metastasis model. The retroviral cDNA library generated from the highly-metastatic mouse melanoma B16-BL6 cell line was introduced into noncancerous CHO cells (CHO/library). Mouse received an intravenous injection of the CHO/library, and cells surviving 28 days after the injection were collected from the lung and named CHO-M1 cells. CHO-M1 cells were intravenously inoculated, and then CHO-M2 cells were separated using the same in vivo selection. Two cDNA inserts were amplified from the genomic DNA of those cells (Fig. 1A) . We read the sequence of the lower band and identified it as Merm1/Wbscr22. Merm1/Wbscr22 is one of the genes in the chromosomal region that is deleted in Williams-Beuren syndrome (6) . Although
Merm1 is known to have a typical domain of methyltransferase (SAM-dependent MTase fold) and a nuclear localization signal (7), no studies have discussed the functions of Merm1. Human melanoma A375M cells, which are known as highly-metastatic tumor cells (26) , showed strong nuclear Merm1 expression (Fig. 1B) . To verify the specificity of the antibody, we confirmed Merm1 expression by Western blotting (Fig. 1C) .
Immunohistochemistry of tissue array on which various cancer tissues were spotted showed strong Merm1 expression in invasive ductal carcinomas (IDCs) compared to corresponding normal tissues (Fig. 1D ). An additional analysis using tissue array of IDC suggested that Merm1 expression were frequently up-regulated in IDCs (25/50; 50%).
IDC is a very common type of breast cancer that is likely to invade lymph and blood systems. About 10% of all cases are diagnosed as metastatic IDC in the first medical examination. IDC prognosis is evaluated by histopathological grades (27). As shown in and contains non-charged small amino acids such as glycine (28, 29) . In fact, substitution of these glycines with other amino acids has been used to destroy methyltransferase activity (30) . We generated methyltransferase-dead Merm1 (Merm1-MD) in which the Gly residues in the DXGXGXGXXG motif were substituted with Arg (DXRXRXRXXR). CHO cells were infected with retroviral vectors encoding nothing (CHO/mock), mouse Merm1-WT (CHO/Merm1-WT) or mouse Merm1-MD (CHO/Merm1-MD) ( Fig. 2A) . CHO/Merm1-WT, but not CHO/mock and CHO/Merm1-MD, formed many metastatic foci in the lungs and livers (Fig. 2B) . This suggested that the intact SAM-dependent MTase fold of Merm1 was essential for promoting metastasis. No significant difference was observed in in vitro and in vivo proliferation (Supplementary Interestingly, Merm1 expression was correlated with their metastatic ability in mouse tumor cells of the same origin. We generated short hairpin RNAs (shRNAs) targeting mouse and human Merm1 (Figs. 3B and 3C) . Consistent with the results of ectopic expression in CHO cells (Fig. 2B) , Merm1 knock-down inhibited experimental metastasis of A375M cells to the lungs and spontaneous metastasis of LM8 cells to the lungs (Fig. 3D) . We then ascertained that Merm1 knock-down inhibited tumor survival in the lung microvasculature (Fig. 3E) and did not affect the in vitro or in vivo proliferation ( Supplementary Fig. S2A and S2B ). Merm1 was suggested to enhance tumor cell survival in the vasculature, resulting in increased metastasis formation. We performed comparative transcriptome analysis using cDNA microarray.
LM8/shRNA2 cells were compared to LM8/control cells, and A375M/shRNA2 cells were compared to A375M/control cells. Merm1 knock-down was confirmed in both LM8 and A375M cells (Fig. 4A) . There was no significant difference in the expression levels of cell adhesion-relating molecules (selectins, cadherins, and CAMs). An adhesion assay of A375M cells to human umbilical vein endothelial cells (HUVECs) confirmed that Merm1 was not likely to affect tumor cell adhesion to vascular endothelial cells ( Supplementary Fig. S2C ). We used the threshold of 2-fold increase or decrease to select significant genes (Supplementary Tables S1 and S2). Only one gene, Zac1/Lot1/Plagl1, satisfied the criteria in both LM8 and A375M cells. The transcription of Zac1 was up-regulated by Merm1 knock-down in both cell lines (Fig. 4A) . We confirmed the negative correlation between Merm1 and Zac1 in LM8 and A375M cells at both the mRNA and the protein levels (Fig. 4B) . We also found a negative correlation between Merm1 and Zac1 expression in 14 other human tumor cell lines (Fig. 4C) . These results suggest that Merm1 has a negative effect on Zac1 transcription.
Methyltransferases containing a SAM-dependent MTase fold regulate gene transcription via DNA or histone methylation activity (25, 26) . However, Merm1 does not possess the characteristic catalytic center (Pro-Cys motif) and DNA-binding motif of DNA methyltransferases (33) . Therefore, we assumed that Merm1 mediated histone methylation, but not DNA methylation. We, thus, examined H3-Lys9 and -Lys27 methylation states in the Zac1 promoter region. H3-Lys9 methylation in the Zac1 promoter region (-424 to -308) was observed in A375M/control cells, but not in A375M/shRNA2 cells (Fig. 4D) , and H3-Lys27 methylation was not observed in either cell line. These findings suggested that Merm1 repressed Zac1 expression by direct or indirect H3-Lys9 methylation in the Zac1 promoter region. To specify the direct link between Merm1 and H3-Lys9 methylation of the Zac1 promoter, we performed an in vitro methylation assay using recombinant histone H3 and Merm1. However, purified Merm1 did not methylate histone H3 in this assay. Merm1 might require native conditions or functionally associated proteins to methylate histone H3. We then generated Zac1 shRNAs and found that shRNA3 and shRNA4 effectively attenuated Zac1 expression (Fig. 5A ). Nutlin-3 inhibits p53 degradation by interfering with the p53-MDM2 interaction (34) . The amount of the p53-regulated pro-apoptotic factor p53AIP1 (35) increased in proportion to the p53 accumulation due to Nutlin-3 (Fig.   5B ). In the presence of 30 μM Nutlin-3, Merm1 knock-down enhanced the expression of p53AIP1, and this effect was eliminated by simultaneous Zac1 knock-down. An annexin V-PI staining assay confirmed that actual level of apoptosis (Fig. 5C ). Merm1 knock-down increased the population of cells in late apoptosis (annexin V positive, PI positive), but Zac1 knock-down reduced the same population. Thus, Merm1 inhibited p53 transcriptional activity through Zac1 repression, resulting in apoptosis inhibition.
Consistent with these results, Zac1 knock-down rescued Merm1 knock-down-mediated cell death in the vasculature (Fig. 5D ). We also confirmed that Zac1 knock-down eliminated the inhibition of metastasis by Merm1 knock-down (Fig. 5E ). Our results indicate that Merm1 promoted metastasis formation by enhancing cell survival in the vasculature via suppressing Zac1-p53-dependent apoptosis.
Merm1-mediated metastasis promotion can be realized on the premise that tumor cells have a normal p53 function. Sequence analysis of cDNA isolated from LM8, SBC3, KM12 and A375M cells showed that they didn't have a mutation in p53 protein, including its DNA-binding domain ( Supplementary Fig. S3A and S3B ). On the other hand, MDA-MB-231 cells, which had mutant p53 ( Supplementary Fig. S3A ), and Saos-2, which are known to lose the coding region of p53 (36) , expressed very low levels of Merm1 (Fig. 3A) . CHO cells also had a mutation in the DNA-binding domain of p53 (Supplementary Fig. S3C ). However, this mutation of p53 (T211K) was reported to abrogate its ability to induce cell-cycle arrest but have no effect on its ability to down-regulate DNA replication (37) . Mutant p53 of CHO cells probably retain partial p53 function involving apoptosis initiation, and this could explain why CHO cells could acquire metastatic ability by ectopic expression of Merm1 (Fig. 2B) . These suggest that Merm1 suppresses persisting p53 function through repression of Zac1, leading to acquisition of metastatic ability. 
Discussion
Recently, the presence of chemotherapy-resistant cancer cells, e.g., dormant cancer cells or cancer stem cells, has been shown to be involved in metastasis formation (38, 39) . These cells are growing very slowly or not at all, rendering proliferation-targeting therapies ineffective. In other words, these cells are just surviving. To establish effective treatments for metastasis, it is necessary to identify and understand the specific mechanisms that control tumor cell survival. In this study, we discovered a novel mechanism that promotes cell survival and metastasis by inhibiting p53-dependent apoptosis. Although deletion and mutation of p53 are not the first-hit mutations in tumor initiation, p53 inactivation is important in subsequent tumor progression (40). In the vasculature, tumor cells must overcome immunologic assault or mechanical shear forces, and almost all tumor cells die (3, 19) . Such cell death partly depends on p53.
Zhang et al. showed that hypoxia in the primary tumor up-regulated MDM2 expression and decreased p53 protein levels, which rendered tumor cells less sensitive to apoptosis and more prone to metastasis (18) . In another study, Lewis et al. showed that the absence of functional p53 induced metastasis without affecting primary tumor growth in a mouse model (23) . Here we clarified a novel critical mechanism of p53 inactivation during the process of metastasis formation. Merm1 inhibited p53-dependent apoptosis by repressing the p53 coactivator Zac1 and promoted tumor cell survival in the vasculature. Because Merm1 had no effect on tumor proliferation ( Supplementary   Fig. S1 , S2A and S2B), the enhanced cell survival in the vasculature appears to be directly reflected in the metastatic capacity of tumor cells. Furthermore, Merm1 expression enhanced metastasis to both the lungs and livers (Fig. 2B) , indicating that Merm1 does not affect tumor proliferation in an organ-specific manner.
Our results indicate that Merm1 is a potential target for controlling cancer metastasis.
Because Merm1 was originally isolated form mouse melanoma cell lines, we tried to examine the expression of Merm1 in melanoma clinical samples. Although we found significant up-regulation of Merm1 expression at the mRNA level in melanoma, there was no relationship between Merm1 up-regulation and poor prognosis of melanoma.
We are now collecting tissue sections of melanoma for further analysis with immunohistochemistry. In breast cancer, we found strong expression of Merm1 in tumor tissues (Fig. 1D) , whereas another group reported Zac1 down-regulation, which we believe could have resulted from Merm1 expression (15) . Because Merm1-targeting therapy would be effective only when tumor cells had normal p53 function, we need to 
